Royalty Pharma(RPRX) - 2024 Q3 - Quarterly Results

Exhibit 99.1 1 ROYALTY PHARMA REPORTS THIRD QUARTER 2024 RESULTS • Portfolio Receipts growth of 15% to $735 million; Royalty Receipts growth of 15$704 million • Capital Deployment of approximately $1.2 billion • Raising full year 2024 guidance: Portfolio Receipts expected to be$2,750 to $2,800 million NEW YORK, NY, November 6, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2024 and raised full year 2024 gui ...